Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Implications of Isolated Bone Failure Without Systemic Disease Progression During EGFR-TKI Treatment.

Clinical lung cancer - 1 Nov 2016

Hwang Ji An, Lee Ji Young, Kim Woo Sung, Song Joon Seon, Rho Jin Kyung, Choi Chang-Min, Lee Jae Cheol

Abstract excerpt

BACKGROUND: We investigated the characteristics of patients with epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) who had experienced isolated progression of bone metastases without aggravation of extraskeletal organs during EGFR-tyrosine kinase inhibitor (TKI) treatment. MATERIALS AND METHODS: We retrospectively reviewed the data from 870 patients with EGFR-mutant NSCLC treated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Bone Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Neoplasm Recurrence, Local

Share to Neoplasm Staging

Share to Protein Kinase Inhibitors

Share to Survival Rate

Source

Identifiers

PMID: 27378173
DOI: 10.1016/j.cllc.2016.05.018

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Implications of Isolated Bone Failure Without Systemic Disease Progression During EGFR-TKI Treatment.PMID 27378173Read ↗

Prognosis of different bone metastases patterns in EGFR-mutant advanced lung adenocarcinoma patientsSemantic proximity Read ↗

Assessing EGFR-mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy.Semantic proximity Read ↗

Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis.Semantic proximity Read ↗

Analysis of Progression Patterns and Failure Sites of Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Receiving First-line Treatment of Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations.Semantic proximity Read ↗

Femoral bone metastasis is a poor prognostic factor in osimertinib-treated patients with EGFR-mutated non-small cell lung cancer: a retrospective, multicenter studySemantic proximity Read ↗

Femoral bone metastasis is a poor prognostic factor in osimertinib-treated patients with EGFR-mutated non-small cell lung cancerSemantic proximity Read ↗

Isolated Brain Metastases as the First Relapse After the Curative Surgical Resection in Non-Small-Cell Lung Cancer Patients With an EGFR Mutation.Semantic proximity Read ↗

[Impact of bone metastasis on the prognosis of lung adenocarcinoma patients treated with third-generation EGFR-TKI and the underlying mechanisms].Semantic proximity Read ↗

[Local treatment combined with EGFR-TKIs for advanced non-small cell lung cancer with solitary progression during EGFR-TKI treatment].Semantic proximity Read ↗

Prediction of skeletal-related events in patients with non-small cell lung cancer.Semantic proximity Read ↗

Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.